European Medicines Agency

Doc. Ref. EMEA/96630/2008
P/9/2008

EUROPEAN MEDICINES AGENCY DECISION

of 29 February 2008

on the application for agreement of a Paediatric Investigation Plan for Cozaar and associated names, losartan potassium EMEA-000008-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

© European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged.

EUROPEAN MEDICINES AGENCY DECISION

of 29 February 2008

on the application for agreement of a Paediatric Investigation Plan for Cozaar and associated names, losartan potassium EMEA-000008-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme (Europe) Inc. on 28 June 2007 under Article 16.1 of Regulation (EC) No 1901/2006 as amended also including a request for a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, formulated on 18 January 2008, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation, and of its own motion in accordance with Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given a positive opinion,

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a waiver.

(4) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for Cozaar and associated names, losartan potassium, 12.5, 25, 50 and 100 mg, film-coated tablets, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for Cozaar and associated names, losartan potassium, 12.5, 25, 50 and 100 mg, film-coated tablets, oral use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A deferral for for Cozaar and associated names, losartan potassium, 12.5, 25, 50 and 100 mg, film-coated tablets, oral use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Merck Sharp & Dohme (Europe) Inc., 5 Clos du Lynx, B-1200 Brussels, Belgium.

Done at London, 29 February 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

EMEA/96630/2008
EMEA-000008-PIP01-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A REQUEST FOR AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN FOR

Scope of the application

Active substance:
Losartan potassium

Invented name:
Cozaar and associated names

Condition(s):
Hypertension
Proteinuria
Heart failure

Pharmaceutical form(s):
Film coated tablets
Age appropriate, commercial, liquid formulation

Route(s) of administration:
Oral route

Name/corporate name of the PIP applicant:
Merck, Sharp & Dohme (Europe) Inc

Information about the authorised medicinal product:
see Annex II

Basis for opinion

Pursuant to Article 16.1 of Regulation (EC) No 1901/2006 as amended, Merck, Sharp & Dohme (Europe) Inc submitted for agreement to the EMEA a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 02 August 2007.

Supplementary information was provided by the applicant on 20 November 2007.
A meeting with the Paediatric Committee took place on 16 January 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

© European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,
- to grant a deferral in accordance with Article 21 of Regulation (EC) No 1901/2006 as amended
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended and concluded in accordance with
  Article 11(1)(a) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population
  Article 11(1)(c) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients

The Icelandic and the Norwegian Paediatric Committee member(s) do agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix(ces).

London, 18 January 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S) / DISEASE(S)

Hypertension

Proteinuria

Heart failure

B. WAIVER

- **Condition**

Hypertension

Proteinuria

- **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:

- Preterm newborn infants, Term newborn infants (0-27 d), Infants (28 d-5 m) for film-coated tablets and age appropriate, commercial liquid formulation for oral use

- **Condition**

Heart failure

- **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:

- All subsets of the paediatric population for tablets and age appropriate, commercial liquid formulation for oral use

C. PAEDIATRIC INVESTIGATION PLAN

C.1. Condition to be investigated

Hypertension

Proteinuria

- **Subset(s) covered:**
  Infants & toddlers (6-24 m), Children (2-11 y), Adolescents (12-16/18 y)

- **Formulation(s):**
  Film-coated tablets
  Age appropriate, commercial liquid formulation

- **Studies / Measures:**

Area	Subarea	Number	Description
Clinical	Efficacy and Safety	1	Efficacy and safety study in proteinuria with or without hypertension in children 1-17 years
Clinical	Dose-ranging study	1	Open label dose-ranging study in children 6 months to 6 years with hypertension
Quality	Formulation	1	Age appropriate, commercial liquid formulation

Need for paediatric measures in a EU-Risk Management Plan: Yes
Date of completion of the paediatric investigation plan: February 2009
A deferral has been granted: Yes